COVID-19
vaccine AZD1222 showed robust immune responses in all participants in Phase I/II
trial ---- the COVID-19 vaccine candidate AZD1222
in up to 1,077 healthy adults in five trial centres
in the UK. Participants aged 18-55 years
Development
of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all
adult age groups ---- Trial
enrolling up to 30,000 adults aged 18 years or
over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention
of COVID-19
Advancing our discovery of novel coronavirus-neutralising antibodies against COVID-19
University
of Oxford potential COVID-19 vaccine Phase III clinical trial initiated in the US ---- Trial
enrolling up to 30,000 adults to assess safety,
efficacy and immunogenicity of the vaccine for the prevention of COVID-19
AZD1222
US Phase III primary analysis confirms safety and efficacy
沒有留言:
張貼留言
請網友務必留下一致且可辨識的稱謂
顧及閱讀舒適性，段與段間請空一行